QQQ   437.93 (+0.61%)
AAPL   180.14 (-0.71%)
MSFT   408.77 (+0.26%)
META   487.39 (+0.70%)
GOOGL   137.08 (+0.51%)
AMZN   174.67 (+0.87%)
TSLA   200.25 (-0.89%)
NVDA   791.40 (+1.90%)
NIO   5.66 (+4.24%)
AMD   189.52 (+7.35%)
BABA   74.07 (-0.70%)
T   17.00 (+0.24%)
F   12.40 (+0.81%)
MU   89.70 (-0.01%)
CGC   3.28 (-2.38%)
GE   155.76 (+0.10%)
DIS   111.06 (+0.23%)
AMC   4.28 (-14.23%)
PFE   26.76 (-1.04%)
PYPL   60.34 (+0.15%)
XOM   104.68 (+0.35%)
QQQ   437.93 (+0.61%)
AAPL   180.14 (-0.71%)
MSFT   408.77 (+0.26%)
META   487.39 (+0.70%)
GOOGL   137.08 (+0.51%)
AMZN   174.67 (+0.87%)
TSLA   200.25 (-0.89%)
NVDA   791.40 (+1.90%)
NIO   5.66 (+4.24%)
AMD   189.52 (+7.35%)
BABA   74.07 (-0.70%)
T   17.00 (+0.24%)
F   12.40 (+0.81%)
MU   89.70 (-0.01%)
CGC   3.28 (-2.38%)
GE   155.76 (+0.10%)
DIS   111.06 (+0.23%)
AMC   4.28 (-14.23%)
PFE   26.76 (-1.04%)
PYPL   60.34 (+0.15%)
XOM   104.68 (+0.35%)
QQQ   437.93 (+0.61%)
AAPL   180.14 (-0.71%)
MSFT   408.77 (+0.26%)
META   487.39 (+0.70%)
GOOGL   137.08 (+0.51%)
AMZN   174.67 (+0.87%)
TSLA   200.25 (-0.89%)
NVDA   791.40 (+1.90%)
NIO   5.66 (+4.24%)
AMD   189.52 (+7.35%)
BABA   74.07 (-0.70%)
T   17.00 (+0.24%)
F   12.40 (+0.81%)
MU   89.70 (-0.01%)
CGC   3.28 (-2.38%)
GE   155.76 (+0.10%)
DIS   111.06 (+0.23%)
AMC   4.28 (-14.23%)
PFE   26.76 (-1.04%)
PYPL   60.34 (+0.15%)
XOM   104.68 (+0.35%)
QQQ   437.93 (+0.61%)
AAPL   180.14 (-0.71%)
MSFT   408.77 (+0.26%)
META   487.39 (+0.70%)
GOOGL   137.08 (+0.51%)
AMZN   174.67 (+0.87%)
TSLA   200.25 (-0.89%)
NVDA   791.40 (+1.90%)
NIO   5.66 (+4.24%)
AMD   189.52 (+7.35%)
BABA   74.07 (-0.70%)
T   17.00 (+0.24%)
F   12.40 (+0.81%)
MU   89.70 (-0.01%)
CGC   3.28 (-2.38%)
GE   155.76 (+0.10%)
DIS   111.06 (+0.23%)
AMC   4.28 (-14.23%)
PFE   26.76 (-1.04%)
PYPL   60.34 (+0.15%)
XOM   104.68 (+0.35%)
NASDAQ:IPA

ImmunoPrecise Antibodies (IPA) Stock Price, News & Analysis

$1.89
+0.08 (+4.42%)
(As of 12:53 PM ET)
Today's Range
$1.78
$2.00
50-Day Range
$1.31
$2.41
52-Week Range
$0.94
$4.34
Volume
39,703 shs
Average Volume
85,326 shs
Market Capitalization
$49.74 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$8.00

ImmunoPrecise Antibodies MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
342.0% Upside
$8.00 Price Target
Short Interest
Healthy
0.24% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.43mentions of ImmunoPrecise Antibodies in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.32) to ($0.20) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.00 out of 5 stars

Medical Sector

542nd out of 958 stocks

Pharmaceutical Preparations Industry

260th out of 450 stocks


IPA stock logo

About ImmunoPrecise Antibodies Stock (NASDAQ:IPA)

ImmunoPrecise Antibodies Ltd., together with its subsidiaries, operates as a biotherapeutic research and technology company in Canada and internationally. It provides NonaVac DNA for complex protein classes, including GPCRs and ion channels; and Rapid Prime, a positive monoclonal antibodies for generating anti-idiotypic antibodies, and producing monoclonal antibodies against conformational epitopes. The company also offers syngeneic cell line for immunization and screening; and peptide production for subsequent antibody discovery campaign. In addition, it provides B cell select platform which allows for the interrogation of animal antibody repertoire; screening of the immune repertoire of rabbits and chickens and select the desired antibody directly from the B cells; single step hybridoma, a semi-solid media to grow mouse and rat hybridomas; and DeepDisplay, a combination of transgenic animal platform and custom IPA phage display antibody selection. The company also offers phage display, a custom immune libraries from multiple species; and CAR development, an adaptable antibody which allows the inclusion of functional data early in the screening funnel. Further, it provides silico developability, a profiling toolset for antibody lead candidates; and vitro analytical tools for the study of various critical quality attributes. Additionally, the company offers LucinaTech, an antibody humanization to identify essential framework and CDR residues; antibody affinity maturation for therapeutic and diagnostic application; and antibody chimerization for cloning and production of variable antibody domain. It also provides Eurofins preclinical services; hybrid service model, a service model designed to reduce time and risk with custom technologies and applications; and breadth and depth to accelerate assay development, screening cascades, drug candidate validation, and new biotherapeutic concepts. The company was incorporated in 1983 and is headquartered in Victoria, Canada.

IPA Stock Price History

IPA Stock News Headlines

Is Gold Really Boring?
Many investors perceive gold as a "boring" investment. But according to MoneyWeek, that's a good thing. Gold helps investors sleep soundly as it preserves wealth and creates a hedge against inflation. Today, there's a unique way to invest in gold, with real advantages over coins and mining stocks.
IPA Announces Proposed Public Offering of Common Shares
Is Gold Really Boring?
Many investors perceive gold as a "boring" investment. But according to MoneyWeek, that's a good thing. Gold helps investors sleep soundly as it preserves wealth and creates a hedge against inflation. Today, there's a unique way to invest in gold, with real advantages over coins and mining stocks.
ImmunoPrecise Antibodies Announces CFO Transition
ImmunoPrecise Antibodies (IPA) Receives a Buy from H.C. Wainwright
IPA Announces Board Refreshment
IPA Responds to 13D Filing
See More Headlines
Receive IPA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ImmunoPrecise Antibodies and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
12/14/2023
Today
2/29/2024
Next Earnings (Estimated)
3/21/2024
Fiscal Year End
4/30/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:IPA
Fax
N/A
Employees
102
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$8.00
High Stock Price Target
$9.00
Low Stock Price Target
$7.00
Potential Upside/Downside
+344.4%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$-19,980,000.00
Pretax Margin
-74.24%

Debt

Sales & Book Value

Annual Sales
$22.63 million
Book Value
$1.74 per share

Miscellaneous

Free Float
24,518,000
Market Cap
$47.37 million
Optionable
Not Optionable
Beta
0.09
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Key Executives

  • Dr. Jennifer Lynne Bath Ph.D.
    CEO, President & Non-Independent Director
  • Dr. Ilse Roodink
    Chief Scientific Officer & Interim General Manager of IPA Europe, Oss
  • Ms. Kristin Taylor CPA
    M.B.A., Chief Financial Officer
  • Mr. David E. Orton
    Chief Operating Officer
  • Dr. Roland Romijn
    Head of General Operations of the Utrecht site of IPA (Europe)














IPA Stock Analysis - Frequently Asked Questions

Should I buy or sell ImmunoPrecise Antibodies stock right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for ImmunoPrecise Antibodies in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" IPA shares.
View IPA analyst ratings
or view top-rated stocks.

What is ImmunoPrecise Antibodies' stock price target for 2024?

2 equities research analysts have issued 1 year target prices for ImmunoPrecise Antibodies' shares. Their IPA share price targets range from $7.00 to $9.00. On average, they expect the company's stock price to reach $8.00 in the next year. This suggests a possible upside of 342.0% from the stock's current price.
View analysts price targets for IPA
or view top-rated stocks among Wall Street analysts.

How have IPA shares performed in 2024?

ImmunoPrecise Antibodies' stock was trading at $1.71 at the start of the year. Since then, IPA shares have increased by 5.8% and is now trading at $1.81.
View the best growth stocks for 2024 here
.

Are investors shorting ImmunoPrecise Antibodies?

ImmunoPrecise Antibodies saw a increase in short interest during the month of February. As of February 15th, there was short interest totaling 50,800 shares, an increase of 232.0% from the January 31st total of 15,300 shares. Based on an average daily volume of 116,200 shares, the days-to-cover ratio is currently 0.4 days. Currently, 0.2% of the company's shares are short sold.
View ImmunoPrecise Antibodies' Short Interest
.

When is ImmunoPrecise Antibodies' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 21st 2024.
View our IPA earnings forecast
.

How were ImmunoPrecise Antibodies' earnings last quarter?

ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA) announced its earnings results on Thursday, December, 14th. The company reported ($0.07) earnings per share for the quarter, topping analysts' consensus estimates of ($0.09) by $0.02. The business had revenue of $4.50 million for the quarter, compared to analyst estimates of $4.44 million. ImmunoPrecise Antibodies had a negative net margin of 70.81% and a negative trailing twelve-month return on equity of 28.32%.

Who are ImmunoPrecise Antibodies' major shareholders?

ImmunoPrecise Antibodies' stock is owned by many different institutional and retail investors. Top institutional investors include Ingalls & Snyder LLC (4.87%), Northern Trust Corp (0.23%), Citadel Advisors LLC (0.00%), Simplex Trading LLC (0.00%) and Concourse Financial Group Securities Inc. (0.00%).

How do I buy shares of ImmunoPrecise Antibodies?

Shares of IPA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:IPA) was last updated on 2/29/2024 by MarketBeat.com Staff